The role of PET-FDG when there is diagnostic doubt concerning relapse or radionecrosis of cerebral tumours;Papel de la PET-FDG ante la duda diagnostica de recidiva frente a radionecrosis en tumores cerebrales

Revista de Neurologia

Volumn 27, Issue 157, 1998, Pages 447-452

  Asensio, C ^a  

^a NONE

Author keywords

Cerebral tumour; Nuclear magnetic resonance; PET FDG; Radionecrosis; Tumour relapse

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN METABOLISM; BRAIN TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE; OLIGODENDROGLIOMA; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; RADIATION NECROSIS; RADIODIAGNOSIS; TUMOR RECURRENCE;

EID: 0031692322     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.27157.98185     Document Type: Article

References (20)

1. Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Pui MH, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996; 36: 1251-61.
2. DiChiro G, Oldfield E, Wright DC. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol 1988; 150: 189-97.
3. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995; 36: 159-64.
4. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79: 115-26.
5. Carreras JL. La Tomografía por Emisión de Positrones en Oncología. Instituto de España. Real Academia Nacional de Medicina 1995.
6. Antar MA, Barnett GH, McIntyre WJ, Quigley MR, Sargent B. Can brain thallium 201 SPECT substitute for FDG-PET in detecting recur rent brain tumor in the presence of radiation necrosis; correlation with biopsy/surgery results. J Nucl Med 1994; 35: 223. (Abstract).
7. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994; 73: 2386-94.
8. 18F] Fluoro-2-deoxy-D-glucose in low-grade glioma. Neurosurgery 1996; 39: 470-7.
9. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-8.
10. Patronas NJ, DiChiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816-22.
11. Coleman RE, Hoffman JM, Hanson MW. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991; 32: 616-22.
12. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38: 1459-62.
13. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on PET-guided stereotactic biopsy. Cancer 1996; 78: 1098-106.
14. Coleman RE, Hoffman JM, Hanson MW, Sostman D, Schold SC. Clinical application of PET for evaluation of brain tumors. J Nucl Med 1991; 32: 616-22.
15. Valk PE, Dillon WP. Radiation injury of the brain. Am J Neuroradiol 1991; 12: 45-62.
16. 99mTc-HMPAO. Am J Roentgenol 1992; 158: 399-404.
17. Go KG, Keuter EJ, Kamman RL, Pruim J, Metzemaekers JD, Staal MJ, et al. Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994; 34: 994-1002.
18. Maldonado A, Calvo F, Gómez M, Llamas JM, Soria R, Montz R, et al. Aportación de la PET-FDG al diagnóstico diferencial recidiva tumoral vs radionecrosis en tumores del SNC. S N 1997; 2: 137-48.
19. 18F] FDG. Resultados obtenidos en el Centro PET Complutense. Rev Esp Med Nuclear 1997; 16: 26-31.
20. Strauss LG, Schad L, Dimitrakopoulou-Strauss A, Knopp M, Debus J, Oberdorfer F, et al. PET with F-18-FDG and O-15-Water and GDDTPA MRI in patients with brain tumors receiving radiotherapy. Eur J Nucl Med 1997; 8: 372P. (Abstract).